Li Ding, PhD

Research Program Solid Tumor Therapeutics
Li Ding

Researcher Background

Primary Academic Title

David English Smith Distinguished Professor of Medicine; Section Director – Computational Biology

Education

  • 1991: BS in Biology, Fudan University, Shanghai, China
  • 1998: PhD in Biochemistry, University of Utah School of Medicine, Salt Lake City, UT
  • 2000: Postdoctoral Fellow, Department of Biochemistry, Stanford University School of Medicine, Palo Alto, CA

Research & Select Publications

Research Interest

Cancer genomics and proteomics

Research Publications

A 15-layer multi-omics analysis of gastric cancer ecotypes provides therapeutic insights.
Authors:

Wang Y, Olsen LK, Jiao F, one or more additional authors omitted Ding L, one or more additional authors omitted Zhang B

Journal & Year:

Cell Rep Med • 2026

Longitudinal Profiling of Tumor and Immune Compartments Uncovers Patterns of Dysregulation and Associations with Response in Multiple Myeloma.
Authors:

Ohlstrom DJ, Pilcher WC, Michaud ME, one or more additional authors omitted Ding L, one or more additional authors omitted Bhasin MK

Journal & Year:

Blood Cancer Discov • 2026

Cellular senescence in human liver under normal aging and cancer.
Authors:

Karpova A, Li X, Peng CW, one or more additional authors omitted Ding L

Journal & Year:

Cell Genom • 2026

Integrative proteogenomic analysis provides molecular insights and clinical significance in gallbladder cancer.
Authors:

Fu Z, Song Y, Liu F, one or more additional authors omitted Ding L, one or more additional authors omitted Fan J

Journal & Year:

Cancer Cell • 2026

Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial.
Authors:

Kong T, Mabry A, Highkin M, one or more additional authors omitted Ding L, one or more additional authors omitted Ma CX

Journal & Year:

Nat Commun • 2026

A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma.
Authors:

Pilcher WC, Yao L, Gonzalez-Kozlova E, one or more additional authors omitted Ding L, one or more additional authors omitted Bhasin M

Journal & Year:

Nat Cancer • 2026

Advancing biological understanding of cellular senescence with computational multiomics.
Authors:

Li S, Agudelo Garcia PA, Aliferis C, one or more additional authors omitted Ding L, one or more additional authors omitted Fan R

Journal & Year:

Nat Genet • 2025

Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures.
Authors:

Satpathy S, Clark NM, Chen YJ, one or more additional authors omitted Ding L, one or more additional authors omitted Gillette MA

Journal & Year:

Cancer Cell • 2025

Combined Flt3L and CD40 agonism restores dendritic cell-driven T cell immunity in pancreatic cancer.
Authors:

Hogg GD, Weinstein AG, Kingston NL, one or more additional authors omitted Ding L, one or more additional authors omitted DeNardo DG

Journal & Year:

Sci Immunol • 2025

Germline genetic variation impacts clonal hematopoiesis landscape and progression to malignancy.
Authors:

Liu J, Tran D, Xue L, one or more additional authors omitted Ding L, one or more additional authors omitted Bolton KL

Journal & Year:

Nat Genet • 2025

Precision proteogenomics reveals pan-cancer impact of germline variants.
Authors:

Martins Rodrigues F, Terekhanova NV, Imbach KJ, one or more additional authors omitted Ding L

Journal & Year:

Cell • 2025

Multi-omic and spatial analysis of mouse kidneys highlights sex-specific differences in gene regulation across the lifespan.
Authors:

Chen S, Liu R, Mo CK, one or more additional authors omitted Ding L, Chen F

Journal & Year:

Nat Genet • 2025

Proteogenomic characterization of non-functional pancreatic neuroendocrine tumors unravels clinically relevant subgroups.
Authors:

Ji S, Cao L, Gao J, one or more additional authors omitted Ding L, one or more additional authors omitted Yu X

Journal & Year:

Cancer Cell • 2025

Germline predisposition in multiple myeloma.
Authors:

Martins Rodrigues F, Jasielec J, Perpich M, one or more additional authors omitted Ding L

Journal & Year:

iScience • 2025

RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia.
Authors:

Kong T, Laranjeira ABA, Letson CT, one or more additional authors omitted Ding L, one or more additional authors omitted Oh ST

Journal & Year:

Nat Commun • 2025